STING1 and neoplasm: Tumor-Intrinsic Biomarkers (Baseline/pre-ablation; Day −7 to 0): Assessment of tumor expression of innate-immune suppressors, such as RECQL4 or TRIM6, should be performed before ablation (Day −7 to Day 0) to identify patients who may be intrinsically resistant to ablation-induced STING activation and who could benefit from combination therapy with specific innate agonists [147].